{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:48:51Z","timestamp":1791373731643,"version":"4.3.1"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.1737","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:02:49Z","timestamp":1585324969000},"page":"e201737","source":"Crossref","is-referenced-by-count":184,"title":["Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity"],"prefix":"10.1001","volume":"3","author":[{"given":"Faheem","family":"Farooq","sequence":"first","affiliation":[{"name":"Deparment of Pediatrics and Medicine, Stony Brook University Hospital, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Mogayzel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton","family":"Haywood","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Berman Institute of Bioethics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Strouse","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"issue":"3","key":"zoi200088r2","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ppul.v49.3","article-title":"Cystic fibrosis in a Hispanic adolescent.","volume":"49","author":"Lin","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"zoi200088r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2015.10.002","article-title":"Epidemiology of cystic fibrosis.","volume":"37","author":"Spoonhower","year":"2016","journal-title":"Clin Chest Med"},{"issue":"10","key":"zoi200088r4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.2014.11011","article-title":"Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia.","volume":"312","author":"Herrick","year":"2014","journal-title":"JAMA"},{"issue":"2865","key":"zoi200088r5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia a molecular disease.","volume":"110","author":"Pauling","year":"1949","journal-title":"Science"},{"issue":"3","key":"zoi200088r6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0006-3002(58)90516-X","article-title":"Abnormal human haemoglobins, I: the comparison of normal human and sickle-cell haemoglobins by fingerprinting.","volume":"28","author":"Ingram","year":"1958","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"zoi200088r7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1172\/JCI104410","article-title":"The effect of methemoglobin formation in sickle cell disease.","volume":"40","author":"Beutler","year":"1961","journal-title":"J Clin Invest"},{"issue":"4","key":"zoi200088r8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/jama.1970.03180040039008","article-title":"Health care priority and sickle cell anemia.","volume":"214","author":"Scott","year":"1970","journal-title":"JAMA"},{"issue":"3","key":"zoi200088r9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM197001152820312","article-title":"Sickle-cell anemia: high prevalence and low priority.","volume":"282","author":"Scott","year":"1970","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200088r10","first-page":"344","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study.","volume":"56","author":"Andersen","year":"1938","journal-title":"AJDC"},{"issue":"4922","key":"zoi200088r11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis.","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"issue":"4922","key":"zoi200088r12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"4922","key":"zoi200088r13","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: chromosome walking and jumping.","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"issue":"18","key":"zoi200088r14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi200088r15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi200088r16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del.","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200088r17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/jama.2014.15939","article-title":"The anatomy of medical research: US and international comparisons.","volume":"313","author":"Moses","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"zoi200088r19","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S.","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"11","key":"zoi200088r21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/gim.2012.76","article-title":"Birth prevalence of disorders detectable through newborn screening by race\/ethnicity.","volume":"14","author":"Feuchtbaum","year":"2012","journal-title":"Genet Med"},{"issue":"5","key":"zoi200088r22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/(ISSN)1098-2272","article-title":"Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state.","volume":"13","author":"Lorey","year":"1996","journal-title":"Genet Epidemiol"},{"issue":"5","key":"zoi200088r23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort.","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"zoi200088r25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ajh.v84:6","article-title":"The cost of health care for children and adults with sickle cell disease.","volume":"84","author":"Kauf","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"zoi200088r26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jval.2012.12.003","article-title":"Understanding the costs of care for cystic fibrosis: an analysis by age and health state.","volume":"16","author":"van Gool","year":"2013","journal-title":"Value Health"},{"key":"zoi200088r27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CEOR","article-title":"The burden of cystic fibrosis in the Medicaid population.","volume":"10","author":"Hassan","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"zoi200088r29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMp1700101","article-title":"Sickle cell disease\u2014a history of progress and peril.","volume":"376","author":"Wailoo","year":"2017","journal-title":"N Engl J Med"},{"issue":"127","key":"zoi200088r30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1183\/09059180.00008112","article-title":"Personalised medicine for cystic fibrosis: treating the basic defect.","volume":"22","author":"Elborn","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"2","key":"zoi200088r32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.semperi.2009.12.006","article-title":"History and current status of newborn screening for hemoglobinopathies.","volume":"34","author":"Benson","year":"2010","journal-title":"Semin Perinatol"},{"issue":"3","key":"zoi200088r33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation.","volume":"21","author":"Scharff","year":"2010","journal-title":"J Health Care Poor Underserved"},{"issue":"7","key":"zoi200088r34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002501","article-title":"Multiple citation indicators and their composite across scientific disciplines.","volume":"14","author":"Ioannidis","year":"2016","journal-title":"PLoS Biol"},{"issue":"2","key":"zoi200088r35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jama.2009.1987","article-title":"Funding of US biomedical research, 2003-2008.","volume":"303","author":"Dorsey","year":"2010","journal-title":"JAMA"},{"issue":"12","key":"zoi200088r40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia.","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200088r41","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.","volume":"74","author":"Platt","year":"1984","journal-title":"J Clin Invest"},{"key":"zoi200088r42","first-page":"929","article-title":"Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.","volume":"7","author":"O\u2019Reilly","year":"2013","journal-title":"Drug Des Dev Ther"},{"issue":"21","key":"zoi200088r43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood.V124.21.86.86","article-title":"A phase 3 study of l-glutamine therapy for sickle cell anemia and sickle \u00df0-thalassemia.","volume":"124","author":"Niihara","year":"2014","journal-title":"Blood"},{"issue":"9","key":"zoi200088r44","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease.","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi200088r45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi200088r46","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications.","author":"Mall","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"zoi200088r47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease.","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi200088r48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events.","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi200088r49","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","article-title":"Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.","volume":"102","author":"Arnold","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"zoi200088r50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bbmt.2017.11.018","article-title":"Experiences and decision making in hematopoietic stem cell transplant in sickle cell disease: patients\u2019 and caregivers\u2019 perspectives.","volume":"24","author":"Khemani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"zoi200088r51","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric Hematopoietic Stem Cell Transplantation.","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"zoi200088r52","first-page":"29","article-title":"Gene therapy for the treatment of cystic fibrosis.","volume":"5","author":"Burney","year":"2012","journal-title":"Appl Clin Genet"},{"issue":"1","key":"zoi200088r53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1542\/peds.2007-2875","article-title":"Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders.","volume":"123","author":"Grosse","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"zoi200088r54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/MPH.0000000000000013","article-title":"Insurance status as a sociodemographic risk factor for functional outcomes and health-related quality of life among youth with sickle cell disease.","volume":"36","author":"Robinson","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"zoi200088r55","doi-asserted-by":"publisher","first-page":"i95","DOI":"10.1136\/bmjqs-2013-002790","article-title":"Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative.","volume":"23","author":"Marshall","year":"2014","journal-title":"BMJ Qual Saf"},{"issue":"16","key":"zoi200088r57","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2015.3075","article-title":"Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.","volume":"313","author":"Stettler","year":"2015","journal-title":"JAMA"},{"issue":"17","key":"zoi200088r58","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease.","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"4","key":"zoi200088r59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1513\/AnnalsATS.201706-486OC","article-title":"Association of high-dose ibuprofen use, lung function decline, and long-term survival in children with cystic fibrosis.","volume":"15","author":"Konstan","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"zoi200088r60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"9257","key":"zoi200088r61","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(00)04132-5","article-title":"Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study.","volume":"357","author":"Wierenga","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"zoi200088r62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7326\/M16-0858","article-title":"Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study.","volume":"166","author":"Stephenson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi200088r64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.1947.02880010035011","article-title":"Sickle cell anemia, a race specific disease.","volume":"133","year":"1947","journal-title":"JAMA"},{"issue":"10","key":"zoi200088r66","first-page":"1721","article-title":"Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis.","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"zoi200088r67","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1378\/chest.14-2189","article-title":"Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California.","volume":"149","author":"Buu","year":"2016","journal-title":"Chest"},{"issue":"18","key":"zoi200088r68","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16183280","article-title":"Understanding multilevel factors related to urban community trust in healthcare and research.","volume":"16","author":"Webb Hooper","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"zoi200088r69","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11606-014-2986-7","article-title":"Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease.","volume":"29","author":"Haywood","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi200088r70","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4410","article-title":"Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study.","volume":"2","author":"Sinha","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi200088r71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/01612840.2018.1443530","article-title":"Stigma of sickle cell disease: a systematic review.","volume":"39","author":"Bulgin","year":"2018","journal-title":"Issues Ment Health Nurs"},{"key":"zoi200088r73","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-015-0281-2","article-title":"How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the US Food and Drug Administration.","volume":"10","author":"Furlong","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"zoi200088r75","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/hesr.v54.s2","article-title":"Discrimination in the United States: experiences of black Americans.","volume":"54","author":"Bleich","year":"2019","journal-title":"Health Serv Res"},{"key":"zoi200088r1","volume-title":"Data & Statistics on Sickle Cell Disease","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"zoi200088r18","volume-title":"Report on NIH Funding vs. Global Burden of Disease","author":"National Institutes of Health","year":"2018"},{"key":"zoi200088r20","volume-title":"Patient Registry Annual: Data Report","author":"Cystic Fibrosis Foundation","year":"2017"},{"key":"zoi200088r24","volume-title":"Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)","author":"National Institutes of Health","year":"2017"},{"key":"zoi200088r31"},{"key":"zoi200088r36","author":"PhRMA","year":"2018"},{"key":"zoi200088r37","volume-title":"Insights Into Rare Disease Drug Approval: Trends and Recent Developments","author":"Lanthier","year":"2017"},{"key":"zoi200088r56","volume-title":"Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014","author":"National Heart, Lung, and Blood Institute","year":"2014"},{"key":"zoi200088r63","volume-title":"Institute of Medicine Committee on Understanding Eliminating Racial Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care","author":"Smedley","year":"2002"},{"key":"zoi200088r65","doi-asserted-by":"crossref","DOI":"10.56021\/9780801883255","volume-title":"The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease","author":"Wailoo","year":"2006"},{"key":"zoi200088r28","unstructured":"US Trust; Indiana University Lilly Family School of Philanthropy. High net worth philanthropy: charitable practices and preferences of wealthy households. October 2016. Accessed February 22, 2020. https:\/\/scholarworks.iupui.edu\/bitstream\/handle\/1805\/11234\/high-net-worth_oct_2017-1.pdf?sequence=4&isAllowed=y"},{"key":"zoi200088r38","unstructured":"WalkerJ, RockoffJD. Cystic Fibrosis Foundation sells drugs rights for $3.3 billion: the biggest royalty purchase ever reflects group\u2019s share of Kalydeco sales. Wall Street Journal. November 19, 2014. Accessed February 24, 2020. https:\/\/www.wsj.com\/articles\/cystic-fibrosis-foundation-sells-drugs-rights-for-3-3-billion-1416414300"},{"key":"zoi200088r39","unstructured":"SeltzerR. Endowment returns slow: survey offers peek at spending. Inside Higher Ed. January 31, 2019. Accessed February 22, 2020. https:\/\/www.insidehighered.com\/news\/2019\/01\/31\/college-endowments-returned-82-percent-2018-annual-survey-adds-some-insight-how"},{"key":"zoi200088r72","unstructured":"Cystic Fibrosis Foundation. Annual report 2018. Accessed February 21, 2020. https:\/\/www.cff.org\/About-Us\/Assets\/2018-Annual-Report.pdf"},{"key":"zoi200088r74","unstructured":"Health Resources and Services Administration. Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program. Accessed February 21, 2020. https:\/\/www.hrsa.gov\/grants\/find-funding\/hrsa-17-078"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2763606\/farooq_2020_oi_200088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:10:20Z","timestamp":1695967820000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2763606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1737","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]}}}